BRIEF published on 08/28/2024 at 13:05, 1 year 5 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 5 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 1 year 5 months ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 5 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 1 year 6 months ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 1 year 6 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 6 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 7 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 1 year 7 months ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 02/13/2026 at 22:15, 2 hours 33 minutes ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 7 hours 3 minutes ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 10 hours 13 minutes ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/13/2026 at 14:30, 10 hours 18 minutes ago Golden Harp Resources Inc. Receives TSXV Final Acceptance and Closes Acquisition to Create District-Scale Copper Hill Land Package
Published on 02/13/2026 at 19:20, 5 hours 28 minutes ago Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 5 hours 46 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 6 hours 27 minutes ago GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 6 hours 40 minutes ago EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range
Published on 02/13/2026 at 17:58, 6 hours 49 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/13/2026 at 18:05, 6 hours 43 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 6 hours 43 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 6 hours 58 minutes ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 6 hours 58 minutes ago Nombre total d'actions et droits de vote - janvier 2026
Published on 02/13/2026 at 17:34, 7 hours 13 minutes ago Déclaration des transactions sur actions propres réalisées du 02/02/2026 au 06/02/2026
